Skip to main content
CNO logo

CNO · CNO Financial Group, Inc.

Track CNO — free
$56.58 -0.60 (-1.05%) At close · Nov 17
Market Cap
$5.17B
Shares
91.35M
Volume · Nov 17 588.29K Avg daily vol (3M) 954.98K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$56.58 Open$56.70 Day$56.03–57.13 52W close$39.55–58.49 Avg vol 30d871K Short int2.6M · 2.8% of shares · 2.7d Short vol57% Last earningsOct 30, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 5, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 13
Current report 8-K
Tax-protection rights plan extended through November 13, 2029

CNO Financial Group, Inc. extended its Section 382 Rights Agreement through November 13, 2029 and updated the purchase price. The agreement is expected to be submitted for shareholder approval at the 2027 annual meeting.

Entered into a material agreement, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change Read from the first part of this long document
5 source passages
On November 13, 2026, CNO Financial Group, Inc. (the “Company”) entered into a Sixth Amended and Restated Section 382 Rights Agreement, dated November 13, 2026 (as the same may be amended from time to time, the “Amended Rights Agreement”) with Equiniti Trust Company, LLC, as successor to American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agent”). The Amended Rights Agreement is intended to help protect the Company’s tax net operating loss carryforwards. Extend the final expiration date of the Amended Rights Agreement to November 13, 2029; Update the purchase price of the Rights; and The Company expects to submit the Amended Rights Agreement to the Company’s shareholders for approval at the Company’s 2027 annual meeting of shareholders. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter net operating income rises to $179.1 million

CNO reported third-quarter net operating income of $179.1 million, up from $127.2 million, while insurance product margin rose to $333.0 million from $300.5 million.

Revenue $1.09B ▼ 8.6% Net income $161.1M ▲ 597.4% Diluted EPS $1.71 ▲ 612.5%
Read from the MD&A section
3 source passages
Net operating income was $179.1 million in the third quarter of 2026 compared to $127.2 million in the third quarter of 2025, and was $399.9 million in the first nine months of 2026 compared to $295.8 million in the first nine months of 2025. Insurance product margin was $333.0 million in the third quarter of 2026 compared to $300.5 million in the third quarter of 2025, and was $868.9 million in the first nine months of 2026 compared to $801.8 million in the first nine months of 2025. CNO is the top tier holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. Open the document at this passage
Oct 30
Earnings call
Raises 2026 Operating EPS Guidance to $5.05 to $5.15

CNO reported third-quarter operating earnings per diluted share up 47% and raised 2026 operating earnings per share guidance to $5.05 to $5.15. A $270 million reserve cession to its Bermuda affiliate took effect October 1st.

3 source passages
Operating earnings per diluted share were up 47% in the third quarter and up 43% year-to-date. Turning to our 2026 guidance on slide 12, based on our strong third quarter performance and outlook for the fourth quarter, we are raising our full year operating earnings per share guidance to a range of between $5.05 to $5.15. Effective October 1st, we ceded approximately $270 million of U.S. statutory graded benefit life reserves from Colonial Penn Life Insurance Company to our Bermuda company. Open the document at this passage
Oct 29
Current report 8-K
Financial results

CNO Financial Group reported third-quarter 2026 net income of $161 million and operating EPS growth of 47%, raised 2026 operating EPS guidance with its midpoint up 9%, and reinsured approximately $270 million of Colonial Penn life statutory reserves.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.54B
Trailing 12 months
Net income (TTM)
$417.60M
Trailing 12 months
Revenue growth YoY
-8.6%
Year over year
Operating margin
14.8%
Trailing 12 months
P / E (TTM)
12.9
Trailing earnings · reciprocal yield 7.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
1.2%
Trailing 12 months
Shares change YoY
-4.4%
Year over year · fewer shares
Price change (1Y)
+42.4%
Trailing year
Short interest
2.8%
Latest settlement · 2.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 30, 2026
Q3 FY26

TL;DR. CNO delivered strong earnings, sales, margin, investment-income and ROE growth and raised full-year operating EPS guidance. Key offsets included higher Medicare Supplement morbidity, lower consumer NAP and fee income, nonrecurring investment-income outperformance, higher TechMod expense and larger realized investment losses.

Bullish
  • + Full-year operating EPS guidance was raised, with the midpoint up 9% from prior guidance.
  • + Operating EPS increased 47% in the quarter and 43% year to date.
  • + CNO delivered a 17th consecutive quarter of sales growth and a 15th consecutive quarter of producing agent growth.
  • + Total insurance product margin excluding significant items increased 7%.
  • + Total net investment income increased 13% year over year, marking a 12th consecutive quarter of growth.
  • + Trailing 12-month operating ROE was 15.4%, or 14.1% excluding significant items.
Bearish
  • − Medicare supplement results reflected higher morbidity, partly offset by block growth and rate increases.
  • − Total consumer life and health NAP declined year over year against a strong comparison.
  • − Fee income declined 72% year over year to $(1.1) million.
  • − Favorable alternative investment income contributed approximately $12 million above the long-term yield estimate, but management did not expect that contribution to continue.
  • − TechMod expense increased to $10.1 million in 3Q26 from $7.2 million in 3Q25.
  • − Net realized investment losses increased to $48.3 million from $8.8 million.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very Low
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +14%
above
Price vs 50-day avg +3%
above
RSI (14) 53
neutral
MACD trend Negative
52-week position 90%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +22%
trailing
YTD return +33%
this year
Relative strength +25%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $55 › 200d $49 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +64 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.81% of shares out · ▼ -6.0% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
401 holders — near 3-yr high, broad support
Squeeze score 56
elevated · 0–100
Fundamentals
Fair
Revenue growth +1%
Y/Y
EPS growth −41%
Y/Y
Valuation P/E 12.9
in line
Buyback $240.4M
remaining
Quant / Vol
risk profile
Very Low
Volatility 21%
annualized · 1-yr
Max drawdown −11%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 29, 2026
Operating EPS · 2026 Non-GAAP Raised $5.05 – $5.15
Jul 30, 2026 $4.60 – $4.80 changed to Oct 29, 2026 $5.05 – $5.15
Free cash flow · 2026 Raised $220M – $240M
Jul 30, 2026 $200M – $250M changed to Oct 29, 2026 $220M – $240M
RBC Ratio · 2026 Maintained 360% – 390%
Jul 30, 2026 360% – 390% changed to Oct 29, 2026 360% – 390%
Holding company liquidity · 2026 at least $150M
Effective tax rate · 2026 Non-GAAP 20.5%
Minimum holding company liquidity · 2026 Non-GAAP $150M
Expense ratio · 2026 Non-GAAP Lowered 18.6% – 18.8%
Jul 30, 2026 18.8% – 19% changed to Oct 29, 2026 18.6% – 18.8%
Debt to total capital ratio · 2026 Non-GAAP Maintained 25% – 28%
Apr 30, 2026 25% – 28% changed to Oct 29, 2026 25% – 28%
Previous outlook earlier release · from the Earnings Call filed Jul 31, 2026

Still-open targets the latest release did not restate under the same label.

Operating earnings per share · full year 2026 $4.60 – $4.80

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+14% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
53 Neutral
MACD trend
Negative Bearish
52-week position
90% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $55 › 200d $49 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +64 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.81% of shares out · ▼ -6.0% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
401 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $40 Now $57 · 90% Range high $58
vs 200-day avg +14% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Collected premiums from annuity and interest-sensitive life products $603.3M the second quarter of 2026 filing —
Interest margin/average net insurance liabilities 0.1% the second quarter of 2026 filing —
Margin excluding advertising expense/insurance policy income 34% the second quarter of 2026 filing —
Margin from interest-sensitive life $26.4M the second quarter of 2026 filing —
Margin from long-term care $40.6M the second quarter of 2026 filing —
Margin from Medicare supplement $36.5M the second quarter of 2026 filing —
Margin from supplemental health $70.1M the second quarter of 2026 filing —
Margin from traditional life $44.8M the second quarter of 2026 filing —
Total health margin $147.2M the second quarter of 2026 filing —
Total health margin margin/insurance policy income 34% the second quarter of 2026 filing —
Total investment income not allocated to product lines $49.4M the second quarter of 2026 filing —
Total life margin $71.2M the second quarter of 2026 filing —
Underwriting margin $26.1M the second quarter of 2026 filing —
Underwriting margin/insurance policy income 52% the second quarter of 2026 filing —
Annuity Account Values $13.71B 2Q26 —
Annuity Collected Premiums $536M 2Q26 —
Annuity margin non-GAAP $60.6M 2Q 2026 —
associates 3,200 As of 2026 —
Average Book Value of Investments & Cash $32.71B 2Q26 —
average cost per repurchased share $46.57 2Q26 —
Average Yield on Allocated Investments 4.91% 2Q26 —
Book value per common share, excluding accumulated other comprehensive loss non-GAAP $40.72 Jun-26 —
Book Value per Diluted Share x AOCI non-GAAP $39.92 2Q26 —
Book value per diluted share, excluding accumulated other comprehensive income (loss) non-GAAP $39.92 As of June 30, 2026 —
Client Assets in BD and Advisory non-GAAP $5.69B 2Q26 —
Client Assets in Brokerage and Advisory at end of period $5.69B 2Q26 —
common shares outstanding 92.7M As of June 30, 2026 —
common shares repurchased 1.3M 2Q26 —
common stock repurchased $60M 2Q26 —
company dividends paid to the holding company $20M 2Q26 —
Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating non-GAAP $3.5B 2Q26 trailing four quarter average —
consolidated statutory risk-based capital ratio non-GAAP 377% Q2 2026 —
Debt to Capital excluding $500 million note that matured May 2025 non-GAAP 26.1% 2Q26 —
debt-to-total capital ratio, excluding accumulated other comprehensive income (loss) non-GAAP 26.1% As of June 30, 2026 —
dividends paid on common stock $16.8M 2Q26 —
Earned yield 4.88% 2Q26 —
estimated statutory operating gain non-GAAP $35.4M 2Q26 —
exclusive agents 5,100 As of 2026 —
Expense Ratio non-GAAP 18.4% 2Q26 —
Expense Ratio - YTD non-GAAP 18.7% 2Q26 YTD —
Free Cash Flow non-GAAP $30.7M 2Q26 —
Health margin non-GAAP $147.2M 2Q 2026 —
Insurance Product Margin Excluding Significant Items - Annuity non-GAAP $60.6M 2Q26 —
Insurance Product Margin Excluding Significant Items - Fixed Indexed Annuities non-GAAP $49.2M 2Q26 —
Insurance Product Margin Excluding Significant Items - Fixed Interest Annuities non-GAAP $7.8M 2Q26 —
Insurance Product Margin Excluding Significant Items - Health non-GAAP $147.2M 2Q26 —
Insurance Product Margin Excluding Significant Items - Interest Sensitive Life non-GAAP $26.4M 2Q26 —
Insurance Product Margin Excluding Significant Items - Life non-GAAP $71.2M 2Q26 —
Insurance Product Margin Excluding Significant Items - Long-term Care non-GAAP $40.6M 2Q26 —
Insurance Product Margin Excluding Significant Items - Medicare Supplement non-GAAP $36.5M 2Q26 —
Insurance Product Margin Excluding Significant Items - Other Annuities non-GAAP $3.6M 2Q26 —
Insurance Product Margin Excluding Significant Items - Supplemental Health non-GAAP $70.1M 2Q26 —
Insurance Product Margin Excluding Significant Items - Total Margin non-GAAP $279M 2Q26 —
Insurance Product Margin Excluding Significant Items - Traditional Life non-GAAP $44.8M 2Q26 —
Invested Assets $32B as of 6/30/2026 —
Life margin non-GAAP $71.2M 2Q 2026 —
Margin from fixed indexed annuities non-GAAP $49.2M 2Q 2026 —
Margin/average net insurance liabilities non-GAAP 1.74% 2Q 2026 —
Net operating income non-GAAP $491.4M Trailing four quarters ended 2Q26 —
GAAP → non-GAAP reconciliation
GAAP Net income applicable to common stock $125.9M
+$13.6M Net realized investment (gains) losses from sales and impairments
+$1.1M Net change in market value of investments recognized in earnings
+$0M Fair value changes related to the agent deferred compensation plan
-$34.6M Changes in fair value of embedded derivative liabilities and market risk benefits
+$9.7M Expenses related to TechMod initiative
+$0M Goodwill and intangible asset impairment
+$1.1M Net loss related to divested business
+$0.4M Other
+$2.3M Income tax expense (benefit) on non-operating income
= Net operating income $119.5M
Net operating income excluding significant items non-GAAP $119.5M 2Q26 —
New Annualized Premiums non-GAAP $127.7M 2Q26 —
New Money Rate 6.16% 2Q26 —
Operating return on equity, excluding significant items non-GAAP 13.1% Trailing four quarters ended June 30, 2026 —
policies 3.3M As of 2026 —
Policyholder and Client Assets $19.4B 2Q26 —
Pre-tax operating earnings non-GAAP $617.2M Trailing four quarters ended 2Q26 —
Producing Agent Counts (PAC) non-GAAP 5,125 2Q26 —
remaining repurchase authority $300.4M As of June 30, 2026 —
Rolling Twelve Months Expense Ratio non-GAAP 18.5% 2Q26 TTM —
Total insurance product margin non-GAAP $279M 2Q 2026 —
Total Margin $279M 2Q26 —
Total Net Investment Income non-GAAP $327.5M 2Q26 —
TTM operating ROE excluding significant items non-GAAP 13.1% 2Q26 —
unrestricted cash and investments held by holding company $233.2M As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Insurance - Life — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CNO
CNO Financial Group, Inc.
this stock
$5.17B +33.2% +0.9% 12.9 2.8%
CILJF
China Life Insurance Co Ltd
$81.12B -16.8% — — 0.0%
MFC
Manulife Financial Corp
$72.39B +20.8% — — 0.8%
MET
Metlife Inc
$63.79B +28.6% +8.6% 13.2 1.7%
AFL
Aflac Inc
$63.16B +15.8% -9.3% 18.8 1.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
401
% held
95.8%
Net QoQ
-318.4K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
405
View
Short & Settlement
Short Interest Falling
Shares short
2.6M
Days to cover
2.7d
Change
-164.9K sh
View
Short Volume
Short vol %
57%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
84
Value
$4.5K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
54.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Jun 11, 2025
View
Financials
Financials
Revenue (FY)
$4.5B
Net income (FY)
$229.3M
EPS diluted
$2.30
View
Buybacks
Authorized
$500.0M
Remaining
$240.4M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
17

CNO Financial Group, Inc. extended its Section 382 Rights Agreement through November 13, 2029 and updated the purchase price. The agreement is expected to be submitted for shareholder approval at the 2027 annual meeting.

View
Proposed Sales
Value
$1.1M
Shares
20.2K
Filed
Nov 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 30, 2026
View
Investor Relations
Latest news
CNO Financial Group to Present at…
Published
Aug 27, 2026
View

Performance

5D 20D 120D MTD YTD
CNO -2.1% +3.1% +22.4% -1.9% +33.2%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +0.3% +7.9% +25.4% +1.2% +25.8%

Capital returns

Latest dividend
$0.18 / share · ex Sep 10, 2026
Declared · upcoming
$0.18 / share · ex Dec 10, 2026
Raised 5.9%
Paid (TTM)
$0.70 / share · 4 payouts
Dividend yield (TTM, derived)
1.24%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$500.00M
Spent (derived)
$259.60M
Remaining
$240.40M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1224608 CUSIP 12621E103 13F (30d) 403 filings 371 filers Visit website Investor relations